BridgeBio Pharma

BridgeBio Pharma

Yahoo Finance • yesterday

BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026

BridgeBio Pharma, Inc. PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines... Full story

Yahoo Finance • 5 days ago

BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS Says

BridgeBio Pharma's (BBIO) heart disorder drug Attruby faces near-term tailwinds from the likely appr Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news Full access to Financial Times and MT N... Full story

Yahoo Finance • 6 days ago

BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates

BridgeBio Pharma, Inc. - $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31 million sequentially and $145 million year over year). Loss from oper... Full story

Yahoo Finance • 24 days ago

BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drug

[Double exposure microscope Young woman scientific using equipment for research. Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology] jittawit.21/iStock via Getty Images BridgeBio Pharma (BBIO [https:... Full story

Yahoo Finance • 2 months ago

BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?

A month has gone by since the last earnings report for BridgeBio Pharma (BBIO). Shares have lost about 10.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release,... Full story

Yahoo Finance • 2 months ago

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

Rare diseases have moved steadily from being an overlooked corner of medicine to an important frontier for drug innovation. The FDA estimates that more than 7,000 rare diseases affect more than 30 million Americans, while most of these con... Full story

Yahoo Finance • 2 months ago

AM Markets Need to Know: Nasdaq rebounds in August, Anthropic expands AI capacity, and more

[New York City and London multiple exposure image] Stock index futures pointed to a weaker open on Tuesday, setting Wall Street up for a lower start to September as investors monitored renewed tensions in the Middle East. Here are the fi... Full story

Yahoo Finance • 2 months ago

Alnylam drops as AstraZeneca posts full trial results for failed heart drug

[Alnylam Pharmaceuticals, Inc.] hapabapa/iStock Editorial via Getty Images AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) on Friday released full data from a failed Phase 3 trial for its RNA-targeting silencer Wainua, developed w... Full story

Yahoo Finance • 2 months ago

BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum

BridgeBio Pharma BBIO entered the second half of 2026 with Attruby doing most of the commercial heavy lifting. Second-quarter revenues rose 120% year over year and topped the Zacks Consensus Estimate, but the company still posted a wider-t... Full story

Yahoo Finance • 2 months ago

Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?

BridgeBio Pharma BBIO is entering a pivotal commercial stretch. Attruby is scaling quickly, while three late-stage candidates could widen the company's revenue base over the next year. The trade-off is a demanding valuation alongside cont... Full story

Yahoo Finance • 2 months ago

Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue

BridgeBio Pharma BBIO shares have gained 24% in the past three months, far ahead of the S&P 500's 0.7% rise over the same period. The move leaves investors weighing whether improving commercial and pipeline momentum can support further gai... Full story

Yahoo Finance • 3 months ago

BridgeBio outlines three launches with first PDUFA set for November 27, 2026 and RECLAIM-HP readout in next 18 months

Earnings Call Insights: BridgeBio Pharma (BBIO) Q2 2026 MANAGEMENT VIEW * CEO Neil Kumar framed Q2 as a turning point, saying, "it feels like we're at T=0 in BridgeBio's next chapter," and tied near-term value creation to Attruby’s nex... Full story

Yahoo Finance • 4 months ago

Panic grips Ionis Pharmaceuticals investors amid bad news spree

A single failed trial can undo years of work in one trading session, and Ionis Pharmaceuticals (IONS) just went through both consecutively. Ionis Pharmaceuticals lost nearly a quarter of its value on July 9 after its heart drug Wainua fai... Full story

Yahoo Finance • 4 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on July 7... Full story

Yahoo Finance • 4 months ago

Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump

AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing. Continue Reading... Full story

Yahoo Finance • 4 months ago

Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/ Ionis

Oselote/iStock via Getty Images Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Alnylam Pharma (ALNY [https://seekingalpha.com/symbol/ALNY]), and BridgeBio Pharma (BBIO [https://seekingalpha.com/symbol/BBIO]), which market drugs for a... Full story

Yahoo Finance • 4 months ago

BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS... Full story

Yahoo Finance • 4 months ago

BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026

PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions... Full story

Yahoo Finance • 5 months ago

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boyd Gaming, Chipotle Mexican Grill, Conagra, Dollar General, MGM Resorts International, Omnicom Group, Yum! Brands, and More

Quick Read: The AI/Data Center chip rally continued to drive the market higher on Tuesday. Now, legacy tech old-school tech giants are joining the rally, as Hewlett Packard Enterprises had its biggest day ever. Despite the giddy, never-en... Full story

Yahoo Finance • 5 months ago

Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Morgan Stanley upgraded Yum! Brands(YU... Full story